Information Provided By: 
Fly News Breaks for September 12, 2017
EGLT
Sep 12, 2017 | 07:02 EDT
Cantor Fitzgerald analyst Brandon Folkes saying the company's five posters at Pain Week last week reinforced the sales potential of, and need for, abuse deterent products such as Arymo ER. With three approved products and a cash runway through 2020, investors should consider owning Egalet shares, Folkes tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
News For EGLT From the Last 2 Days
There are no results for your query EGLT
